Low dose mifepristone in medical management of uterine leiomyoma - An experience from a tertiary care hospital from North India

Indian Journal of Medical Research

Volumn 137, Issue 6, 2013, Pages 1154-1162

  Kulshrestha, Vidushi ^a   Kriplani, Alka ^a   Agarwal, Nutan ^a   Sareen, Neetu ^a   Garg, Pradeep ^a   Hari, Smriti ^a   Thulkar, Jyoti ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Amenorrhoea; Fbroid; Leiomyoma; Medical management; Mifepristone; Uterine

Indexed keywords

MIFEPRISTONE;

ADULT; ALLERGIC RASH; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BREAST TENDERNESS; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPAREUNIA; ECHOGRAPHY; ENDOMETRIAL THICKNESS; FEMALE; FOLLOW UP; GASTRITIS; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HUMAN TISSUE; LEG CRAMP; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL ABORTION; MENSTRUAL CYCLE; MOOD CHANGE; PAIN ASSESSMENT; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN PIGMENTATION; SOMNOLENCE; TERTIARY HEALTH CARE; UTERUS MYOMA; VISUAL ANALOG SCALE; WEAKNESS;

ADMINISTRATION, ORAL; ADULT; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HORMONE ANTAGONISTS; HUMANS; INDIA; LEIOMYOMA; MENORRHAGIA; MIDDLE AGED; MIFEPRISTONE; PROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 84879515101     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Adamson GD. Treatment of uterine fbroids current fndings with gonadotrophin releasing hormone agonists. Am J Obstet Gynecol 1992; 166: 746-51.
2. Carlson KJ, Nichols DH, Schiff I. Indications of hysterectomy. N Engl J Med 1993; 328: 856-60.
3. Delco V la Marca A, Margante G. Short term treatment of uterine fbromyomas with danazol gynecol. Obstet Invest 1999; 47: 258-62.
4. Stovall TG, Summit RL Jr, Washburn SA, Ling FW. Gonadotropin releasing hormone agonist use before hysterectomy. Am J Obstet Gynecol 1994; 170: 1744-51.
5. Lethaby A, Vollenhoven B, Sowter M. Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fbroids. Cochrane Database Syst Rev 2001:CD000547.
6. Letterie GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL, Collins RL. Effcacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril 1989; 51: 951-6.
7. Pron G, Cohen M, Soucie J, Garvin G, Vanderburgh L, Bell S. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fbroid burden, and impact on life. Fertil Steril 2003; 79: 112-9.
8. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010; 151: 2433-42.
9. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, et al. Cell-type specifc actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260-73.
10. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. PEARL I Study Group. Ulipristal acetate versus placebo for fbroid treatment before surgery. N Engl J Med 2012; 366: 409-20.
11. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009; 21: 318-24.
12. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009; 24: 1870-9.
13. Narvekar N, Critchley HO, Cheng L, Baird DT. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod 2006; 21: 2312-8.
14. Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 2010; 82: 442-52.
15. Murphy AA, Morales AJ, Kettel LM, Yen SSC. Regression of uterine leiomyomata to the antiprogesterone RU 486 dose response effect. Fertil Steril 1995; 64: 187-90.
16. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734-9.
17. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SSC. Regression of uterine leiomyomata in response to antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76: 513-7.
18. Reinsch RC, Murphy AA, Morales AJ, Yen SSC. The effects of RU 486 and leuprolide acetate on uterine artery blood fow in the fbroid uterus. A prospective randomized study. Am J Obstet Gynecol 1994; 170: 1623-8.
19. Yang Y, Zhang S, Li K. Treatment of uterine leiomyoma by two different doses of mifepristone. Zhonghua Fu Chan Ke Za Zhi 1996; 31: 624-6.
20. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003; 101: 243-50.
21. Eisinger SH, Bonfglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and effcacy of low-dose mifepristone for uterine myomas. Minim Invasive Gynecol 2005; 12: 227-33.
22. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006; 108: 1381-7.
23. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008; 112: 1029-36.
24. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol 2009; 49: 77-83.
25. Esteve JL, Acosta R, Pérez Y, Campos R, Hernández AV, Texidó CS. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol 2012; 161: 202-8.
26. Eisinger SH, Fiscella J, Bonfglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 2009; 146: 215-8.
27. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003; 18: 61-8.
28. Heikinheimo O, Ranta S, Grunberg S, Lähteenmäki P, Spitz IM. Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment. Metabolism 1997; 46: 292-6.
29. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004; 103: 1331-6.
30. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000; 65: 741-51.
31. Fiscella J, Bonfglio T, Winters P, Eisinger SH, Fiscella K. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol 2011; 42: 947-53.